15 results on '"Olivia Minelli"'
Search Results
2. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia
- Author
-
Alessandra Carotti, Brunangelo Falini, Massimo F. Martelli, Sara Piccinelli, C. Zucchetti, Loredana Ruggeri, Adelmo Terenzi, Simonetta Saldi, Antonio Pierini, Mauro Di Ianni, Sara Tricarico, Cynthia Aristei, Roberta Iacucci Ostini, Maria Paola Martelli, Olivia Minelli, Mara Merluzzi, Samanta Bonato, Franca Falzetti, Cristina Mecucci, Gianluca Ingrosso, Tiziana Zei, Andrea Velardi, Antonella Mancusi, Sara Ciardelli, Rita Tognellini, and Roberto Limongello
- Subjects
Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Survival rate ,Aged ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Total body irradiation ,medicine.disease ,Fludarabine ,Leukemia, Myeloid, Acute ,Leukemia ,Graft-versus-host disease ,business ,Whole-Body Irradiation ,medicine.drug - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed the 2 remaining major unmet medical needs: leukemia relapse and chronic graft-versus-host disease (cGVHD). Fifty AML patients were enrolled in the study. The conditioning regimen included total body irradiation for patients up to age 50 years and total marrow/lymphoid irradiation for patients age 51 to 65 years. Irradiation was followed by thiotepa, fludarabine, and cyclophosphamide. Patients received an infusion of 2 × 106/kg donor regulatory T cells on day −4 followed by 1 × 106/kg donor conventional T cells on day −1 and a mean of 10.7 × 106 ± 3.4 × 106/kgpurified CD34+ hematopoietic progenitor cells on day 0. No pharmacological GVHD prophylaxis was administered posttransplantation. Patients achieved full donor–type engraftment. Fifteen patients developed grade ≥2 acute GVHD (aGVHD). Twelve of the 15 patients with aGVHD were alive and no longer receiving immunosuppressive therapy. Moderate/severe cGVHD occurred in only 1 patient. Nonrelapse mortality occurred in 10 patients. Only 2 patients relapsed. Consequently, at a median follow-up of 29 months, the probability of moderate/severe cGVHD/relapse-free survival was 75% (95% confidence interval, 71%-78%). A novel HLA-haploidentical HSCT strategy that combines an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy resulted in an unprecedented cGVHD/relapse-free survival rate in 50 AML patients with a median age of 53 years. This trial was registered with the Umbria Region Institutional Review Board Public Registry as identification code 02/14 and public registry #2384/14 and at www.clinicaltrials.gov as #{"type":"clinical-trial","attrs":{"text":"NCT03977103","term_id":"NCT03977103"}}NCT03977103.
- Published
- 2021
3. Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests
- Author
-
Alfonso Iorio, Davide Matino, Anthony K.C. Chan, Stefano Lancellotti, Shen Chu Xie, Monica Sacco, Olivia Minelli, and Raimondo De Cristofaro
- Subjects
Prothrombin time ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Immunology ,Antithrombin ,Cell Biology ,Hematology ,Fibrinogen ,Biochemistry ,Gastroenterology ,ADAMTS13 ,Hemostasis ,Internal medicine ,Medicine ,Plasmapheresis ,business ,medicine.drug ,Blood coagulation test ,Partial thromboplastin time - Abstract
Background : Double filtration plasmapheresis (DFPP) is a form of therapeutic plasma exchange (TPE) that removes high-molecular-weight (HMW) pathological mediators from the plasma with two filters: a plasma separator and a plasma fractionator. Relative to simple TPE, the semi-selectiveness of DFPP reduces protein loss and the need for substitution fluid. However, depending on the choice of plasma fractionator, DFPP may negatively impact hemostatic components such as HMW coagulation factors. Aim: To determine the impact of DFPP on various hemostatic parameters (i.e. FVIII activity, fibrinogen level, vWF level and activity, ADAMTS13 level and activity, protein C (PC) activity, protein S (PS) activity, antithrombin (AT) activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT)). Methods: Fourteen patients undergoing weekly, bimonthly, or monthly DFPP sessions for hematologic conditions (n=11) or nervous system disorders (n=3) were recruited. Hemostatic parameters were measured immediately before and after 27 DFPP sessions (1-4 sessions/patient). The treatment volume was standardized at one plasma volume, and anticoagulation was performed with ACD-A citrate dextrose solution. EC-30W and EC-50W were used as the plasma fractionators in 4 and 23 sessions, respectively. In addition to primary data collection, we systematically searched PubMed, MEDLINE, and EMBASE for studies that investigated the impact of DFPP on hemostasis. No restriction was placed on filter choice. Results: In our cohort of 14 patients, all hemostatic changes were statistically significant. After a routine DFPP session, the level and/or activity of HMW proteins (>100kDa: FVIII, fibrinogen, vWF, ADAMTS13) were decreased more than those of low-molecular-weight (LMW) proteins ( Our systematic review included 26 cohort studies, 6 case reports, and 1 randomized controlled trial. Increases in INR and aPTT following DFPP were considerably higher in previous studies, which may relate to the commonality of heparin-induced anticoagulation. The present study is the first comprehensive investigation of the impact of DFPP on hemostatic parameters with such a large sample size. It is also the first study of its nature to measure ADAMTS13-related parameters. Conclusions: Routine DFPP resulted in significant reduction across all investigated hemostatic proteins and significant prolongation of clotting tests. The activities of HMW coagulation-related proteins were decreased more than those of LMW anticoagulation-related proteins. This finding suggests that DFPP may increase overall bleeding risk, a consideration for patient safety that may be of importance in continuous DFPP treatment. Additional high quality evidence is needed to elucidate the effect of DFPP on the hemostatic system. Disclosures Matino: Sanofi: Honoraria; Sobi: Honoraria, Research Funding; Roche: Research Funding; Bayer: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Bioviiix: Honoraria.
- Published
- 2019
4. Treg/Tcon Immunotherapy and High Dose Marrow Irradiation Ensure Full Control of Leukemia Relapse in Haploidentical Transplantation
- Author
-
Olivia Minelli, Sara Piccinelli, Antonio Pierini, Adelmo Terenzi, Loredana Ruggeri, Cynthia Aristei, Andrea Velardi, Massimo F. Martelli, Simonetta Saldi, Alessandra Carotti, Valentina Lancellotta, and Franca Falzetti
- Subjects
Oncology ,Transplantation ,medicine.medical_specialty ,Adoptive cell transfer ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Hematology ,ThioTEPA ,Hematopoietic stem cell transplantation ,Total body irradiation ,medicine.disease ,Fludarabine ,Leukemia ,surgical procedures, operative ,Internal medicine ,High Risk Acute Leukemia ,medicine ,business ,medicine.drug - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy for patients with high risk of relapse. In spite of that, no matter the donor source or conditioning regimen used, leukemia relapse is still the leading cause of HSCT failure. In HLA-haploidentical HSCT, we recently applied a clinical protocol consisting of total body irradiation (TBI)-based conditioning regimen and a peripheral blood CD34+ cell graft combined with the adoptive transfer of naturally occurring regulatory T cells (Tregs) and conventional T cells (Tcons). No post-transplant pharmacologic GvHD prophylaxis was given. Such protocol was associated with low GvHD and relapse rate (Martelli et al., Blood 2014). To further reduce leukemia relapse in Treg/Tcon-based haploidentical HSCT (Treg/Tcon haplo-HSCT) we used high dose hyper-fractionated TBI (HF-TBI) in the conditioning regimen. We also extended Treg/Tcon haplo-HSCT to patients that are unfit (because of previous comorbidities) and/or too old to withstand high intensity regimens. In these patients the extra-hematologic toxicity of irradiation was reduced with the use of targeted total marrow and lymph node irradiation (TMLI). 40 patients with high risk acute leukemia (36 AML, 4 ALL) received Treg/Tcon haplo-HSCT. All but 3 patients were transplanted in complete remission. 12 younger patients (median age: 28, range: 20-43) received HF-TBI, while 28 older or unfit patients (59, 40-70) received TMLI in the conditioning regimen. HF-TBI (14.4 Gy) was administered in 12 fractions, 3 times a day for 4 days. TMLI was administered by means of Helical Tomotherapy HI-ART (9 fractions, 2 times a day for 4.5 days). Irradiation was followed by chemotherapy with Thiotepa, Fludarabine, and Cyclophosphamide. 2 × 106/kg freshly isolated CD4+CD25+FOXP3+ Tregs were transferred 4 days before the infusion of 1 × 106/kg Tcons and a mega-dose of CD34+ hematopoietic stem cells. No post-transplant pharmacologic GvHD prophylaxis was given. 38/40 patients engrafted. 12 (31%) developed aGvHD grade ³2 (10 are alive and off-therapy). 6 (16%) died because of transplant related complications (2 because of aGvHD, 2 infections, 1 veno-occlusive disease, 1 intracranial hemorrhage). Strikingly, despite the high risk diseases, no patient relapsed after a median follow up of 13 months (range 1-36, Fig. A). Further, only 1 patient developed cGvHD. Thus, cGvHD/Leukemia-free survival was 82% (Fig. B). Treg adoptive transfer allows for the safe infusion of an otherwise lethal dose of donor alloreactive Tcons in the absence of any other form of immune suppression. Our results demonstrate that the potent graft versus leukemia effect of Treg/Tcon adoptive transfer was boosted by high dose marrow irradiation. Thus, this study proves that the right combination of haploidentical Treg/Tcon immunotherapy plus a powerful conditioning regimen can fully eradicate leukemia.
- Published
- 2019
5. The Molecular Spectrum of β- and α-Thalassemia Mutations in Non-Endemic Umbria, Central Italy
- Author
-
Antonella Roetto, Francesco Arcioni, Olivia Minelli, Laura Ceccuzzi, Antonietta Palmieri, Maurizio Caniglia, Cristina Mecucci, Mauro Marchesi, Ylenia Barbanera, Marina Onorato, Paolo Gorello, Antonella Angius, Cecilia Adami, and Antonio Piga
- Subjects
Male ,Thalassemia ,Population ,Clinical Biochemistry ,hemoglobin (Hb) variants ,Hemoglobinopathies ,Italy ,sickle cell disease ,thalassemias ,Emigrants and Immigrants ,Ethnic Groups ,Female ,Humans ,Mutation ,alpha-Thalassemia ,beta-Thalassemia ,Hematology ,Genetics (clinical) ,Biochemistry (medical) ,Alpha-thalassemia ,Gene mutation ,Biology ,Compound heterozygosity ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Ethnicity ,education ,Genetics ,education.field_of_study ,Beta thalassemia ,medicine.disease ,030220 oncology & carcinogenesis ,Cohort ,030215 immunology - Abstract
The aim of this study was to describe the mutational spectrum of hemoglobinopathies during the period 1988-2015 in Umbria, Central Italy, which has never been considered endemic for these conditions. Twenty-four different β-globin gene mutations were identified in 188 patients and eight different α-globin gene mutations in 74 patients. Sixty percent β-thalassemia (β-thal), 85.0% sickle cell disease, 44.0% Hb S (HBB: c.20A>T)/β-thal and 85.0% compound heterozygotes for hemoglobin (Hb) variant-carrying patients were diagnosed or molecularly characterized in the last 3 years. Moreover, most homozygous or compound heterozygous patients (84.5%) came from foreign countries, while only 15.5% were of Italian origin. These data are in accordance with the increasing foreign resident population in Umbria, which has nearly doubled in 10 years (2004-2014). Different from β-globin gene variations, no increasing trend in α defects was observed in our study cohort. Consistently, 58.0% of patients have an Italian origin, suggesting no broad influence of foreign migration in the α-globin genes genetic background. As few defects are prevalent in each country of origin or ethnic group, their knowledge may provide a proper strategy for the identification of mutations in immigrant individuals in a non-endemic region and be important for carrier identification and prenatal screening.
- Published
- 2017
6. Emergency Plasmapheresis in a case of ThromboticThrombocytopenic Purpura (TTP)
- Author
-
Chiara Busti, Mariaserena Pioli Di Marco, Olivia Minelli, and Francesco Guercini
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Vital signs ,Thrombotic thrombocytopenic purpura ,Medicine (miscellaneous) ,Prednisone ,medicine ,Internal medicine ,lcsh:R5-920 ,business.industry ,Plasmapheresis ,medicine.disease ,ThromboticThrombocytopenic Purpura (TTP) ,Emergency ,Schistocyte ,Surgery ,Purpura ,Apheresis ,Business, Management and Accounting (miscellaneous) ,Fresh frozen plasma ,medicine.symptom ,lcsh:Medicine (General) ,business ,medicine.drug - Abstract
An 84 year-old female was admitted to our Department of Vascular Internal Medicine after a sudden onset of weakness on her right side and aphasia along with signs of myocardial ischemia from Electrocardiogram (EKG). Clinical and blood exams led to a suspicion of Moschcowitz syndrome, which was reinforced by the presence of numerous schistocytes on a peripheral blood smear.Due to a rapid deterioration of vital signs as well as alertness, the patient underwent an emergency transfusion and plasmapheresis treatment as recommended by American Society of Apheresis (ASFA) guidelines: one plasma volume was replaced with fresh frozen plasma (FFP) every 24 hours, for the first eight days, in order to reach at least a level of 150,000 platelets/mm3 over three consecutive days accompanied by a decrease in LDH until to 670 UI/l.After this therapy, the clinical picture significantly improved with a complete recovery of consciousness and the disappearance of neurological defects.Examinations to determine the etiology made us hypothesize a secondary status of thrombotic thrombocytopenic purpura due to an autoimmune disorder compatible with Sjogren’s syndrome. The patient was discharged and prescribed prednisone.Currently the patient is in good clinical condition and continues the therapy with prednisone (5 mg/die).
- Published
- 2013
7. Graft engineering for allogeneic haploidentical stem cell transplantation
- Author
-
Stelvio Ballanti, Franco Aversa, Feliciana Battelli, Roberta Iacucci Ostini, Mauro Di Ianni, Olivia Minelli, Katia Fettucciari, Antonella Santucci, Michele Cimminiello, Antonio Tabilio, Monia Capponi, Tiziana Zei, Massimo F. Martelli, Emanuela Rosati, Carla Silvani, Elisabetta Bonifacio, Maria De Ioanni, Franca Falzetti, and Pierfrancesco Marconi
- Subjects
medicine.medical_treatment ,Transplants ,Lymphoproliferative disorders ,Cell Separation ,Human leukocyte antigen ,Hematopoietic stem cell transplantation ,Lymphocyte Depletion ,Hematopoietic Stem Cell Transplantation ,Humans ,Graft Engineering ,haploidentical Transplantation ,medicine ,Molecular Biology ,Tissue Engineering ,business.industry ,Hematopoietic stem cell ,Cell Biology ,Hematology ,medicine.disease ,Histocompatibility ,Transplantation ,Haematopoiesis ,surgical procedures, operative ,medicine.anatomical_structure ,Immunology ,Molecular Medicine ,Stem cell ,business - Abstract
Haploidentical stem cell transplantation has became a clinical reality in the last 10 years as it provides the chance of transplant for about 50% of patients with hematological malignancies who do not have a matched related or unrelated donor. Proper graft preparation for this type of transplant is crucial and this paper analyses our work over the past decade in the search for the optimal graft processing procedure moving from E-rosetting and soybean agglutination, through a combination of negative or positive selection of hematopoietic stem cells to the current method of one-step positive selection. In preparing a graft for haploidentical transplant, three essential requisites must be met. It must contain (1) a megadose (>10 x 10(6) x kg recipient b.w.) of hematopoietic stem cells to overcome the HLA histocompatibility barrier; (2) very few T-lymphocytes (CD3+ cells < 3 x 10(4)/kg recipient b.w.) to prevent severe acute and chronic graft-versus-host disease (GvHD); (3) very few B-lymphocytes to prevent Epstein-Barr virus-related lymphoproliferative disorders. With current graft processing technologies based on positive selection of hematopoietic stem cells, these requirements can be met. A 70-80% hematopoietic stem cell recovery ensures the target megadose is achieved in over 70% of cases with a T-cell depletion of more than 4 logs and a B-cell depletion of over 3 logs. Progress in graft processing has ensured primary, sustained engraftment rates of over 90% and has significantly reduced the incidence of severe acute GvHD and EBV-related lymphoproliferative disorders. Modern time-saving automated graft processing devices ensure reproducibility, reliability, and biological safety, which make widespread application of the haploidentical transplant currently feasible.
- Published
- 2004
8. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma
- Author
-
Massimo F. Martelli, Angelo Vacca, Olivia Minelli, Antonio Tabilio, Franco Dammacco, Roberto Ria, Michele Cimminiello, Mauro Di Ianni, Franca Falzetti, and Stelvio Ballanti
- Subjects
Melphalan ,Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,medicine.medical_treatment ,Urology ,Transplantation, Autologous ,Autologous stem-cell transplantation ,Maintenance therapy ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Antineoplastic Agents, Alkylating ,Busulfan ,Multiple myeloma ,Chemotherapy ,business.industry ,Graft Survival ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Transplantation ,Regimen ,surgical procedures, operative ,Female ,business ,Multiple Myeloma ,medicine.drug ,Stem Cell Transplantation - Abstract
INTRODUCTION High-dose chemotherapy conditioning regimens for autologous stem cell transplantation generally give similar results in multiple myeloma. We compared two regimens: melphalan versus melphalan plus busulphan. METHODS In all, 30 untreated patients with stage III low-risk multiple myeloma were studied. After induction with three VAD courses and mobilization with cyclophosphamide 7 g/m(2) and recombinant human granulocyte-colony stimulating factor (rHuG-CSF) (10 microg/kg b.w./die), they received melphalan 200 mg/m(2) (arm A) or busulphan 16 mg/kg plus melphalan 100 mg/m(2) (arm B) for conditioning for transplantation. All patients received maintenance therapy with Interferon 3 MU x 3/week. RESULTS Time to engraftment after transplantation was similar in both groups. All patients received rHuG-CSF after reinfusion of peripheral stem cells. No differences emerged in transplant-related infective and noninfective complications. There were no transplant-related deaths. A better response was observed in the melphalan plus busulphan regimen (85 versus 75%, P
- Published
- 2004
9. G-CSF-induced thrombocytopenia in a healthy donor
- Author
-
C Silvani, S Plebani, Olivia Minelli, Antonio Tabilio, Franca Falzetti, M Di Ianni, and M Onorato
- Subjects
Transplantation ,Text mining ,business.industry ,Immunology ,Medicine ,Hematology ,Healthy donor ,business - Published
- 2008
10. Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies
- Author
-
S. Poggi, Giorgio Palestro, Dieter Dieneman, Gorm Pallesen, Frederiche Dallenbach, Massimo F. Martelli, Harald Stein, Georges Delsol, Stefano Pileri, Olivia Minelli, and Brunangelo Falini
- Subjects
Pathology ,medicine.medical_specialty ,CD30 ,Lymphoma ,medicine.drug_class ,Ki-1 Antigen ,Biology ,Monoclonal antibody ,Epitope ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Epitopes ,Antigen ,Antigens, Neoplasm ,Histocompatibility Antigens ,medicine ,Humans ,Anaplastic large-cell lymphoma ,Antibodies, Monoclonal ,medicine.disease ,Antigens, Differentiation ,Immunohistochemistry ,Leukemia, Lymphocytic, Chronic, B-Cell ,Paraffin ,Keratins ,Leukocyte Common Antigens ,Lymphoma, Large B-Cell, Diffuse - Abstract
Monoclonal antibodies (mAbs) directed against the leucocyte common (CD45) antigen have been proposed as a useful tool for the differential diagnosis between malignant lymphomas (CD45+) and poorly differentiated nonhemopoietic tumors (CD45-). Thanks to the availability of mAbs directed against fixative-resistant epitopes of the CD45 molecule, this distinction can now easily be made even in routinely processed tissues. However, a small percentage of morphologically poorly defined neoplasms are difficult to diagnose even with the help of immunohistochemistry. The investigators report that 63 out of 165 anaplastic large-cell (ALC) lymphomas did not show any reactivity for the CD45 antigen in paraffin sections. In routine biopsies, the lymphomatous nature of these cases, most of which had been sent for consultation, could be always unequivocally established by demonstrating negativity for cytokeratins (mAb KL1) and clear dot-like and/or surface reactivity with the Ber-H2 mAb, which is directed against a fixative-resistant epitope of the lymphoid cell activation antigen CD30. Strikingly, 54% of the CD45-cases reacted with mAbs directed against fixative-resistant epitopes of the T cell-restricted CD45RO antigen (mAb UCHL1) or the B-restricted molecules CD45RA (mAb 4KB5) and L26 (unclustered). In order to avoid confusion of ALC lymphomas with anaplastic nonlymphoid tumors, pathologists must be aware of the existence of CD30+/CD45- ALC lymphomas, as they can mimic the above-mentioned malignancies both morphologically (due to the sinusoidal growth pattern) and phenotypically (due to the expression of EMA). The investigators conclude that the combined use of mAbs directed against fixative-resistant epitopes of the CD30, CD45RO, CD45RA, and L26 antigens and cytokeratins is essential for the correct diagnosis and treatment of these equivocal cases.
- Published
- 1990
11. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor
- Author
-
Antonio Tabilio, Franco Aversa, Olivia Minelli, and Franca Falzetti
- Subjects
Spontaneous rupture ,Pathology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Spleen ,General Medicine ,Leukapheresis ,Hematopoietic stem cell transplantation ,medicine.disease ,Granulocyte colony-stimulating factor ,medicine.anatomical_structure ,medicine ,Splenic disease ,Stem cell ,Complication ,business - Published
- 1999
12. Use of a panel of monoclonal antibodies for the diagnosis of hairy cell leukaemia. An immunocytochemical study of 36 cases
- Author
-
S. Canino, H. M. Golomb, Gorm Pallesen, David N. Posnett, Brunangelo Falini, E. E. Voxes, L. Annino, David Y. Mason, A. Cafolla, Karen Pulford, Wendy N. Erber, A. Mori, H. Stein, F. Grignani, R. Schwarting, Georges Delsol, C. Ciani, Massimo F. Martelli, and Olivia Minelli
- Subjects
Histology ,Lymphoma ,medicine.drug_class ,PTPRC ,Monoclonal antibody ,Pathology and Forensic Medicine ,Antigen ,Antigens, Neoplasm ,medicine ,Humans ,Lymphocytes ,Leukemia, Hairy Cell ,biology ,Follicular dendritic cells ,Histocompatibility Antigens Class II ,Antibodies, Monoclonal ,General Medicine ,HLA-DR Antigens ,medicine.disease ,Molecular biology ,Leukemia ,Monoclonal ,Antigens, Surface ,biology.protein ,Hairy Cell ,Antibody ,Spleen - Abstract
The phenotype of 36 cases of hairy cell leukaemia has been investigated using a panel of monoclonal antibodies reactive with normal human lymphoid cells and with hairy cells. Staining was performed on frozen sections and/or cell smears by the recently developed APAAP immuno-alkaline phosphatase procedure. In about 90% of cases, neoplastic cells reacted strongly with antibodies against HLA-DR, leucocyte common antigen, B-cells (antibodies B1 and To15), hairy-associated antigens (antibodies KB-90, S-HCL3, HC2) and activated T-lymphocytes (antibodies anti-Tac and Tu69). The phenotype of 10% of cases was clearly different in that the neoplastic cells were negative or only weakly positive for one or more of the antigens recognized by HC2, anti-Tac and Tu69. Antibody HC1 reacted with tumour cells of only 50% of the hairy cell leukaemia cases investigated. Monoclonal antibody Ki-67 (which selectively detects proliferating cells) stained only a low percentage of cells in all but three of the cases studied. The neoplastic cells in all cases were unreactive with monoclonal antibodies anti-Leu1, Tu1, Tu33 and a meshwork of follicular dendritic cells was consistently absent from tissues infiltrated by hairy cells. The immunological phenotype associated with hairy cell leukaemia was not observed in any case of non-Hodgkin's lymphoma, suggesting that it represents a unique type of B-cell neoplasm.
- Published
- 1986
13. Expression of lymphoid-associated antigens on Hodgkin's and Reed-Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies
- Author
-
M F Martelli, S. Canino, L. Flenghi, Harald Stein, B. Falini, Marta Fagioli, R. Farabbi, S. A. Pileri, C. Ciani, Olivia Minelli, and F. Grignani
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,CD30 ,medicine.drug_class ,T-Lymphocytes ,Ki-1 Antigen ,Biology ,Monoclonal antibody ,Pathology and Forensic Medicine ,stomatognathic system ,Nodular sclerosis ,Antigen ,immune system diseases ,Antigens, Neoplasm ,hemic and lymphatic diseases ,medicine ,Humans ,IL-2 receptor ,Lymph node ,B-Lymphocytes ,Antibodies, Monoclonal ,General Medicine ,medicine.disease ,Hodgkin Disease ,Immunohistochemistry ,medicine.anatomical_structure ,Phenotype ,Reed–Sternberg cell ,Lymph Nodes ,CD5 - Abstract
The aim of this study was to elucidate the origin of Hodgkin's and Reed-Sternberg cells. Lymph node cytospins and frozen sections from 20 cases of Hodgkin's disease of different histological subtypes were immunostained by the immunoalkaline phosphatase technique using a panel of monoclonal antibodies. As expected, the Hodgkin's and Reed-Sternberg cells of all cases were positive for the CD30 (Ki-1), CD 15 (hapten X) and CD25 (Tac) antigens. In eight cases, a variable percentage of typical Hodgkin's and Reed-Sternberg cells showed a clear-cut cytoplasmic and/or surface positivity for the T-cell-associated antigens CD3, CD5, CD6 and CD4 (seven cases) or CD8 (one case), but consistently lacked B-cell and macrophage-associated markers. The best visualization of T-cell antigens was obtained in cytocentrifuge preparations and in areas of lymph node frozen sections that had been infiltrated by clusters of Hodgkin's and Reed-Sternberg cells. In two cases of Hodgkin's disease (nodular sclerosis, mixed cellularity) the neoplastic cells weakly expressed the B-cell antigens CD19 and CD22, but not T-cell or macrophage-associated markers. In 10 cases, Hodgkin's and Reed-Sternberg cells were negative for all the lymphoid- and macrophage-associated antigens. These results suggest a lymphoid (either T or B) rather than histiocytic origin for the Hodgkin's and Reed-Sternberg cells in a number of Hodgkin's disease cases.
- Published
- 1987
14. Large cell lymphoma of bone. A report of three cases of B-cell origin
- Author
-
A. Mori, S. Canino, Olivia Minelli, C. Ciani, Stefano Pileri, R. Binazzi, Brunangelo Falini, Francesco Bertoni, Marta Fagioli, and P. Pellicioli
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Histology ,medicine.drug_class ,Bone Neoplasms ,Biology ,Monoclonal antibody ,CD19 ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Immunophenotyping ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Histiocyte ,Aged ,B-Lymphocytes ,Large cell ,Large-cell lymphoma ,Antibodies, Monoclonal ,General Medicine ,medicine.disease ,Immunohistochemistry ,Leukemia, Lymphocytic, Chronic, B-Cell ,Lymphoma ,Phenotype ,biology.protein ,Female ,Antibody - Abstract
Clinicopathological and immunohistological features of three cases of large cell lymphoma of bone are reported. On histological grounds, all the cases were diagnosed as histiocytic lymphomas (Rappaport) or primary centroblastic lymphomas, polymorphic subtype (Kiel). On immunophenotyping, malignant cells strongly reacted with the anti-ieucocyte antibodies PD7/26 and ROS-220C, thereby indicating their lymphomatous nature, and expressed the B-cell antigens CD19 and CD22. Further studies are warranted to determine whether the B-cell phenotype observed in our cases is typical of the majority of primary large cell lymphomas of bone. Immunohistological analysis with monoclonal antibodies is expected to be of great value not only in defining the immunological phenotype of this rare pathological entity, but also in differentiating it from other neoplasms that involve the skeleton, either primarily or secondarily.
- Published
- 1988
15. Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies
- Author
-
L. Flenghi, M F Martelli, Johannes Gerdes, S. Canino, Brunangelo Falini, Olivia Minelli, Marta Fagioli, Stefano Pileri, Stefano Sacchi, C. Ciani, Harald Stein, and Marco Gobbi
- Subjects
Pathology ,medicine.medical_specialty ,Proliferative index ,Lymphoma ,medicine.drug_class ,Monoclonal antibody ,Antigen ,Bone Marrow ,hemic and lymphatic diseases ,medicine ,Humans ,BrdU ,Multiple myeloma ,business.industry ,Antibodies, Monoclonal ,Hematology ,medicine.disease ,Immunohistochemistry ,Leukemia, Lymphoid ,Leukemia ,medicine.anatomical_structure ,Bromodeoxyuridine ,Ki-67 ,monoclonal antibody ,Bone marrow ,business ,Multiple Myeloma ,Cell Division - Abstract
The monoclonal antibody Ki-67, directed against a nuclear antigen expressed by dividing cells in all the phases of cell cycle except G0 and early G1, was used in combination with an anti-BrdU monoclonal antibody, reacting selectively with cells in S-phase, for assessing the percentage of proliferating cells in bone marrow and peripheral blood samples from patients with lymphoma, leukaemia and multiple myeloma. Immunocytochemical labelling of proliferating cells was performed on marrow frozen sections and/or cytospins using an immunoalkaline phosphatase (APAAP) technique that made it possible to obtain proliferative index measurements in a few hours in contrast to the 3–7 d needed with tritiated thymidine. In the 54 marrow lymphoma cases studied a highly significant correlation was observed between the proportion of Ki-67 (+) cells and the separation into low- and high-grade malignant lymphomas according to the Kiel classification. In patients with multiple myeloma at the first diagnosis, the percentage of Ki-67 (+) cells was low (6–10%). In contrast, a high percentage of Ki-67 (+) cells (40–50%) was observed in a young adult with multiple myeloma, in a patient who first presented at the clinical observation with an extradural mass and in three patients who developed extramedullary masses several years after the initial diagnosis of myeloma. In acute lymphoblastic leukaemias of common type the mean value of Ki-67 labelling was 31.3%. Because of their simplicity and rapidity, immunocytochemical techniques may be expected to replace autoradiography and flow cytometry for the detection of proliferating cells in haematological samples.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.